邓务国 - 中山大学 - 肿瘤防治中心

个人简介

邓务国，男，博士, 教授，博士生导师，现受聘于中山大学肿瘤防治中心华南肿瘤学国家重点实验室。1997年在北京大学获得理学博士学位 (专业：生物化学和应用化学)。博士期间, 主要从事黄酮类天然药物抗氧化活性及其与自由基反应机制的研究。1997-1998年, 在中国人民大学化学教研室任讲师。1998-2003年, 在美国德克萨斯大学休斯敦医学院 (The University of Texas Health Science Center Medical School in Houston) 从事博士后研究, 主要进行与炎症和肿瘤相关基因(COX-2/iNOS)的表达调控和分子机制等生物医学领域的研究工作。2003-2009年被聘任到美国排名第一的癌症研究和临床治疗中心-德克萨斯大学M.D.安得森癌症中心 (TheUniversity of Texas M.D. Anderson Cancer Center)工作, 先后任讲师(Instructor)和助理教授 (Assistant Professor), 主要从事肺癌、皮肤癌、乳腺癌的基因治疗和靶向治疗; 抗癌基因 (FUS1和 IL24) 的作用机制和信号传导，以及新型肿瘤分子标记和药物治疗靶点等方面的研究, 并指导博士生和博士后的科研工作。2008年至今，被聘为浙江大学客座教授。2009年9月，任中山大学肿瘤防治中心华南肿瘤学国家重点实验室教授，PI和博士生导师。

研究领域

（1）肺癌、皮肤癌和乳腺癌的发生、发展和转移的信号传导及分子机理; (2) 癌症的基因治疗, 分子靶向治疗和结合治疗,以及这些治疗的分子机制和临床应用；（3）抗癌基因 (如FUS1, IL-24, NPRL2, FHIT，p53) 和致瘤基因 (如COX-2，iNOS，AP-2β, CD70) 的表达调控、信号转导和分子机制; (4)利用最近发展的基因组学和蛋白质组学技术 (如PCR Array, siRNA library screen, SELID-MS and LC-MS-based Protein Chip Arrays) 筛选,发现和鉴定新型的肿瘤分子标记和药物治疗靶点; (5) 新型多功能抗癌纳米药物 (基因纳米药物和多肽纳米药物) 的研究开发, 以及它们在癌症治疗和检测上的临床应用。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathway. Melanoma Res. (in press), 2009. 2. Deng WG, Wu G, Ueda K, Xu K, Roth JA, Ji L. Enhancement of antitumor activity of cisplatin by tumor suppressor FUS1 in human lung cancer cells. Cancer Gene Ther. 15:29-39, 2008. 3. Deng WG, Kawashima H, Wu G, Jayachandran J, Xu K, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with downregulation of MDM2 and activation of Apaf1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 67:709-17, 2007. 4. Deng WG, Montero A, Wu KK. Interferon-gamma suppresses COX-2 promoter activity by inhibiting c-Jun and C/EBP? binding. Arterioscler. Thromb. Vasc. Biol. 27:1752-1759, 2007. 5. Deng WG, Jayachandran G, Xu K, Roth JA, Ji L. Tumor-specific activation of human telomerase reverse transcriptase (hTERT) promoter activity by activating enhancer-binding protein-2? (AP-2?) in human lung cancer cells. J. Biol. Chem. 282:26460-70, 2007. 6. Deng WG, Nishizaki M, Kagawa S, Fang B, Roth JA, Ji L. Induction of apoptosis by FHIT gene via activation of death receptor and caspase cascade signaling pathway in human non-small lung cancer cells. Biochem. Biophys. Res. Commun. 355:993-999, 2007. 7. Lin J, Sun T, Ji L, Deng W, Roth JA, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: Inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26:6989-96, 2007. 8. Ohtani S, Ueda K, Deng W, Wu G, Jayachandran G, Iwamaru A, Kondo S, Atkinson EN, Minna JD, Roth JA, Ji L. A combination treatment with candidate 3p21.3 tumor suppressor 101F6-nanoparticle and ascorbic acid promotes synergistic and selective inhibition of human NSCLC growth via caspase-independent apoptosis and autophagic cell death. Cancer Res. 67:6293-6303, 2007. 9. Deng WG, Tang SZ, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108:518-24, 2006. 10. *Cieslik KA, *Deng WG, (*co-first author), Wu KK. Essential role of C-Rel in nitric oxide synthase-2 transcriptional activation: time-dependent control by salicylate. Mol. Pharmacol. 70:2004-14, 2006 11. Ueda K, Kawashima H, Ohtani S, Deng W, Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA, Kundra V, Ji L. The 3p21.3 Tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 66:9682-90, 2006. 12. Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103: 2135-42, 2004. 13. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha induced cyclooxygenase-2 promoter activation. J. Biol. Chem. 278: 4770-77, 2003. 14. Deng WG, Wu KK. Regulation of nitric oxide synthase expression by p300 coactivator and p50 NF-?B acetylation. J. Immunol. 171:6581-88, 2003. 15. Deng WG, ZhuY, Montero A, Wu KK. Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a treptavidin-agarose pulldown assay. Anal. Biochem. 323:12-8, 2003. 16. Deng WG, Saunders M, He XZ, Yeh H, Wu KK. Identification of cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts. FASEB J. 16:1286-98, 2002. 17. Zhu Y, Saunders M, Yeh H, Deng WG, Wu KK. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding protein. J. Biol. Chem. 277:6923-28, 2002. 18. Schroer K, Zhu Y, Saunders M, Deng WG, Xu XM, Meyer-Kirchrath J, Wu, KK. Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105:2760-65, 2002. 19. Deng WG, Ruan KH, Du M, Saunders M, Wu KK. Aspirin and salicylate bind to BiP and inhibit its ATPase activity in human fibroblasts. FASEB J. 15:2463-70, 2001. 20. *Liou JY, *Deng WG, (*co-first author), Gilroy DK, Wu KK. Colocalization and interaction of cyclooxygenase (COX-2) and caveolin-1 in human fibroblasts. J. Biol. Chem. 276:34975-82, 2001.